跳至主要内容
临床试验/CTRI/2010/091/000092
CTRI/2010/091/000092已完成2 期

A Phase II/III clinical trial to assess safety and immunogenicity of the Pandemic influenza vaccine (Human, live attenuated) A (H1N1) 2009 of SIIL In Adults, Elderly and Pediatric Populations.

Serum Institute of India Ltd0 个研究点目标入组 330 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
330

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Normal healthy subjects of appropriate age. 2.Free of obvious health problems.

排除标准

  • 1.Have a known allergy to eggs or other components of the vaccine.2.pregnancy 3. participating in other clinical trial during the present trial period 4. Altered immune status 5. Acute febrile illness or acute infectious disease or had acute respiratory illness in the previous 7 days. 6. Subject with nasal pathology, History of allergic rhinitis, asthma,child with recurrent wheezing or administration of any intranasal medication. 7. History of a previous severe allergic reaction. 8. History of H1N1 Influenza infection or any influenza vaccination. 9. History of Guillain-Barré Syndrome.10.Children and adolescents with H/o receiving aspirin therapy

研究者

发起方
Serum Institute of India Ltd

相似试验